Claims
- 1. A method for amelioration of proliferative vitreoretinopathy or traction retinal detachment comprising contacting the retinal pigmented epithelial cells of a subject in need thereof with a therapeutic amount of a retinoic acid receptor agonist selected from the group consisting of ethyl-6-�2-(4,4-dimethylthiochroman-6-yl)ethynyl!nicotinate, 6-�2-(4,4-dimethylchroman-6-yl)ethynyl!nicotinic acid, and p-�(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl!-benzoic acid.
- 2. The method of claim 1, wherein proliferative vitreoretinopathy is thereby substantially inhibited.
- 3. The method of claim 1, wherein the agonist is injected into the vitreous cavity.
- 4. The method of claim 1, wherein the therapeutic amount is in the range from about 50 .mu.g to about 150 .mu.g.
- 5. The method of claim 3, wherein the contacting is in a single dose administered within about 24 hours following surgery or trauma.
- 6. The method of claim 3, wherein the contacting is by slow release.
- 7. The method of claim 5, wherein the slow release is from about 3 to 20 days.
- 8. The method of claim 5, wherein the agonist is encapsulated into liposomes.
- 9. The method of claim 5, wherein the agonist is formulated for compaction into microparticulates.
- 10. The method of claim 8, wherein the microparticulates are administered to the scleral pocket or subconjunctival space.
- 11. The method of claim 4, wherein the agonist is dissolved in a biologically inert liquid.
- 12. The method of claim 10, wherein the liquid is silicone oil.
Government Interests
This invention was made with government support under grant no. EY05951 awarded by the National Institutes of Health. The government has certain rights in this invention.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5234926 |
Chandraratna |
Aug 1993 |
|